WELL PHARMACEUTICALS ALLERGY

Posology Do not exceed the stated dose or frequency of dosing. Do not use continuously for more than two weeks without consulting a doctor.

Age Dose Children below 1 year:

Not recommended. 5ml (1mg) twice daily. The minimum interval between the doses should be 4 hours. Maximum daily dose: 5ml (2mg) in any 24 hours. 5ml (1mg) every 4 to 6 hours. Maximum daily dose: 15ml (6mg) in any 24 hours. Children aged 6 - 12 years: 5ml (2mg) every 4 to 6 hours.

Maximum daily dose: 30ml (12mg) in any 24 hours. Adults and children 12 years and over: 10ml (4mg) every 4 to 6 hours. Maximum daily dose: 60ml (24mg) in any 24 hours. Not recommended for children below 1 year Elderly The elderly are more likely to experience neurological anticholinergic effects.

g. a maximum of 12 mg in any 24 hours). Populations Patients with renal and hepatic impairment should seek doctor’s advice prior to taking this medicine. 4 special warnings and precautions for use). Method of administration For oral administration.

The following convention has been utilised for the classification of the frequency of adverse reactions: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1000 to <1/100), rare (>1/10,000 to <1/1000) and very rare (<1/10,000), not known (cannot be estimated from available data).

Adverse reactions identified during post-marketing use with chlorphenamine are listed below. g. increased energy, restlessness, nervousness). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Chlorphenamine in common with other drugs having anticholinergic effects, should be used with caution in epilepsy, raised intra-ocular pressure including glaucoma, prostatic hypertrophy; severe hypertension or cardiovascular disease; bronchitis, bronchiectasis and asthma; hepatic impairment, renal impairment.

g. increased energy, restlessness, nervousness). Avoid use in elderly patients with confusion. Page 3 of 8 The anticholinergic properties of chlorphenamine may cause drowsiness, dizziness, blurred vision and psychomotor impairment in some patients which may seriously affect ability to drive and use machinery.

The effects of alcohol may be increased and therefore concurrent use should be avoided. Chlorphenamine should not be used with other antihistamine containing products, including antihistamine containing cough and cold medicines. Concurrent use with drugs which cause sedation such as anxiolytics and hypnotics may cause an increase in sedative effects, therefore medical advice should be sought before taking chlorphenamine concurrently with these medicines.

Excipients:

This medicine contains sodium methyl parahydroxybenzoate (E219) and sodium propyl parahydroxybenzoate (E217). These may cause allergic reactions (possibly delayed). This medicine contains Maltitol Liquid (E965). Patients with rare hereditary problems of fructose intolerance should not take this medicine.

Maltitol may have mild laxative effect. 1 kcal). This medicine contains 5mg of propylene glycol (E1520) per 5ml which is equivalent to 1mg/ml. This medicine contains less than 1mmol sodium (23mg) per 5ml dose, that is to say essentially sodium free.

Keep out of the sight and reach of children.

1. The anticholinergic properties of chlorphenamine are intensified by monoamine oxidase inhibitors (MAOIs). 5).